| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;93:484-488.)
© 1996 American Heart Association, Inc.
Articles |
Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension
From the Service de Pneumologie et Réanimation Respiratoire, Université Paris-Sud, Hôpital Antoine Béclère, Clamart, France.
Correspondence to François Brenot, MD, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, 157 Rue de la Porte de Trivaux, Clamart 92141, France.
Background The short-term vasodilator response to prostacyclin (PGI2) in patients with primary pulmonary hypertension (PPH) is not only unpredictable but also extremely variable in magnitude. In this retrospective study, we attempted to evaluate in a nonselected population of patients with PPH the degree of vasodilatation achieved during short-term infusion of PGI2 and to investigate whether patients with PPH differed in terms of baseline characteristics and prognoses, according to the level of vasodilatation achieved during initial testing with PGI2.
Methods and Results Between 1984 and 1992, 91 consecutive patients with PPH underwent catheterization of the right side of the heart with a short-term vasodilator trial with PGI2 (5 to 10 ng·kg-1·min-1). According to the level of vasodilatation achieved during PGI2 infusion, patients were divided into three groups: nonresponding (NR, n=40), moderately responding (MR, n=42), and highly responding (HR, n=9) patients. All three groups were defined by a decrease in total pulmonary resistance index (TPRi) of <20%, between 20% and 50%, and >50%, respectively, relative to control values. Prolonged oral vasodilator therapy was subsequently started only in MR and HR patients. All patients had long-term oral anticoagulant therapy. The survival rate at 2 years (transplant recipients excluded) was significantly higher in HR patients compared with NR and MR patients (62% versus 38% and 47% survivors, respectively; P<.05). Comparisons between groups showed no significant differences in baseline hemodynamics or clinical characteristics except for a longer time between onset of symptoms and diagnosis (ie, first catheterization) of PPH in HR patients than in NR and MR patients (71±61 versus 35±34 and 21±21 months, respectively; P<.05).
Conclusions In this study, patients with PPH exhibiting a decrease in TPRi >50% during short-term PGI2 challenge at the time of diagnosis had longer disease evolutions and better prognoses than patients with a lower vasodilator response.
Key Words: hemodynamics • epoprostenol • survival
This article has been cited by other articles:
 |
|
 |
|
  J. D. Edelman Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 110 - 118. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Mukhopadhyay, M. Sharma, S. Ramakrishnan, J. Yusuf, M. D. Gupta, N. Bhamri, V. Trehan, and S. Tyagi Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome: A Preliminary Observational Study Circulation, October 24, 2006; 114(17): 1807 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest, September 1, 2006; 130(3): 841 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Sitbon, M. Humbert, X. Jais, V. Ioos, A. M. Hamid, S. Provencher, G. Garcia, F. Parent, P. Herve, and G. Simonneau Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension Circulation, June 14, 2005; 111(23): 3105 - 3111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, and G. Ahearn Prognosis of Pulmonary Arterial Hypertension*: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 78S - 92S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie, W. Seeger, R. Naeije, G. Simonneau, and L. J. Rubin Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 81S - 88S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, M. Schwaiblmair, R. A. Baumgartner, C. F. Neurohr, T. Kolbe, and J. Behr Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension Chest, February 1, 2004; 125(2): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Mukerjee, D St George, B Coleiro, C Knight, C P Denton, J Davar, C M Black, and J G Coghlan Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach Ann Rheum Dis, November 1, 2003; 62(11): 1088 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle Haemodynamic evaluation of pulmonary hypertension Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin New Treatments for Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216. [Full Text] [PDF]
|
|
|
|
|
|
M.M. Hoeper Pulmonary hypertension in collagen vascular disease Eur. Respir. J., March 1, 2002; 19(3): 571 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. CASTELAIN, D. CHEMLA, M. HUMBERT, O. SITBON, G. SIMONNEAU, Y. LECARPENTIER, and P. HERVE Pulmonary Artery Pressure-Flow Relations after Prostacyclin in Primary Pulmonary Hypertension Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 338 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 British Cardiac Society Guidelines and Medical Pra Recommendations on the management of pulmonary hypertension in clinical practice Heart, September 1, 2001; 86(90001): i1 - 13. [Full Text] [PDF]
|
|
|
|
|
|
V. Castelain, P. Herve, Y. Lecarpentier, P. Duroux, G. Simonneau, and D. Chemla Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1085 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Galie Do we need controlled clinical trials in pulmonary arterial hypertension? Eur. Respir. J., January 1, 2001; 17(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, H. Olschewski, H. A. Ghofrani, H. Wilkens, J. Winkler, M. M. Borst, J. Niedermeyer, H. Fabel, W. Seeger, and the German PPH Study Group A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension J. Am. Coll. Cardiol., January 1, 2000; 35(1): 176 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Atz, I. Adatia, J. E. Lock, and D. L. Wessel Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing J. Am. Coll. Cardiol., March 1, 1999; 33(3): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Mueller, K. Chatterjee, K. B. Davis, M. A. Fifer, C. Franklin, M. A. Greenberg, A. J. Labovitz, P. K. Shah, K. J. Tuman, M. H. Weil, et al. Present use of bedside right heart catheterization in patients with cardiac disease J. Am. Coll. Cardiol., September 1, 1998; 32(3): 840 - 864. [Full Text] [PDF]
|
|